ZA200709483B - Multivalent pneumococcal polysaccharide-protein conjugate composition - Google Patents

Multivalent pneumococcal polysaccharide-protein conjugate composition

Info

Publication number
ZA200709483B
ZA200709483B ZA200709483A ZA200709483A ZA200709483B ZA 200709483 B ZA200709483 B ZA 200709483B ZA 200709483 A ZA200709483 A ZA 200709483A ZA 200709483 A ZA200709483 A ZA 200709483A ZA 200709483 B ZA200709483 B ZA 200709483B
Authority
ZA
South Africa
Prior art keywords
protein conjugate
conjugate composition
pneumococcal polysaccharide
multivalent pneumococcal
multivalent
Prior art date
Application number
ZA200709483A
Other languages
English (en)
Inventor
William P Hausdorff
Siber George Rainer
Peter R Paradiso
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36709976&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200709483(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of ZA200709483B publication Critical patent/ZA200709483B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
ZA200709483A 2005-04-08 2007-11-02 Multivalent pneumococcal polysaccharide-protein conjugate composition ZA200709483B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US66960505P 2005-04-08 2005-04-08

Publications (1)

Publication Number Publication Date
ZA200709483B true ZA200709483B (en) 2009-03-25

Family

ID=36709976

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200709483A ZA200709483B (en) 2005-04-08 2007-11-02 Multivalent pneumococcal polysaccharide-protein conjugate composition

Country Status (29)

Country Link
US (9) US20060228380A1 (xx)
EP (9) EP2425851A1 (xx)
JP (3) JP4472770B2 (xx)
KR (11) KR102017842B1 (xx)
CN (6) CN113198013B (xx)
AR (2) AR053354A1 (xx)
AT (1) ATE548051T1 (xx)
AU (1) AU2006235013B2 (xx)
BR (1) BRPI0607025B8 (xx)
CA (4) CA2878579C (xx)
CL (2) CL2016000566A1 (xx)
CY (1) CY1112777T1 (xx)
DK (1) DK1868645T3 (xx)
ES (1) ES2382048T3 (xx)
HK (3) HK1120416A1 (xx)
HR (1) HRP20120278T1 (xx)
IL (5) IL308456A (xx)
ME (1) ME01334B (xx)
MX (3) MX2007012336A (xx)
MY (1) MY145150A (xx)
NZ (1) NZ562406A (xx)
PL (1) PL1868645T3 (xx)
PT (1) PT1868645E (xx)
RS (1) RS52249B (xx)
SA (1) SA06270323B1 (xx)
SI (1) SI1868645T1 (xx)
TW (3) TWI386222B (xx)
WO (1) WO2006110381A1 (xx)
ZA (1) ZA200709483B (xx)

Families Citing this family (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070184072A1 (en) * 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
EP2425851A1 (en) 2005-04-08 2012-03-07 Wyeth LLC Multivalent Pneumococcal Polysaccharide-Protein Conjugate Composition
US7709001B2 (en) * 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
SI1896065T2 (sl) 2005-06-27 2014-12-31 Glaxosmithkline Biologicals S.A. Postopek za pripravo cepiv
GB0607088D0 (en) * 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
ES2707499T3 (es) 2005-12-22 2019-04-03 Glaxosmithkline Biologicals Sa Vacuna de conjugado de polisacárido neumocócico
AU2013200552B9 (en) * 2006-04-07 2014-07-03 Glaxosmithkline Biologicals S.A. Conjugate vaccines
TW200806315A (en) * 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
AU2012216628B9 (en) * 2006-04-26 2021-10-21 Wyeth Llc Novel Formulations which Stabilize and Inhibit Precipitation of Immunogenic Compositions
AU2016204760A1 (en) * 2006-04-26 2016-07-28 Wyeth Llc Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US8808707B1 (en) 2006-05-08 2014-08-19 Wyeth Llc Pneumococcal dosing regimen
CN101663327B (zh) * 2007-03-23 2014-05-07 惠氏公司 产生肺炎链球菌(streptococcus pneumoniae)荚膜多糖的缩短的纯化方法
WO2008129559A2 (en) 2007-04-23 2008-10-30 Serum Institute Of India Ltd Antigenic polysaccharides and process for their preparation
CN103933564A (zh) * 2007-05-02 2014-07-23 葛兰素史密丝克莱恩生物有限公司 疫苗
RS54349B1 (en) * 2007-06-26 2016-02-29 Glaxosmithkline Biologicals S.A. VACCINE CONTAINING STREPTOCOCCUS PNEUMONIAE Capsular POLYSACCHARIDE CONJUGATES
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
WO2009106085A1 (en) * 2008-02-28 2009-09-03 Nordic Vaccine A/S Vaccine compositions comprising saccharide antigens
US9125863B2 (en) * 2008-05-22 2015-09-08 Children's Medical Center Corporation Synergistic immunogenic fusion protein-polysaccharide conjugate
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
BRPI0922981A8 (pt) * 2008-12-18 2019-11-26 Wyeth Llc método para o controle do peso molecular polissacarídeo para o sorotipo 19a de streptococcus pneumoniae
BRPI0923165A8 (pt) * 2008-12-18 2017-09-12 Wyeth Llc método para a produção de uma solução contendo polissacarídeos capsulares de streptococcus pneumoniae isolados de alto peso molecular, bem como solução contendo os referidos polissacarídeos
BRPI1009828A2 (pt) 2009-03-24 2019-03-12 Novartis Ag adjuvante de proteína de ligação de fator h meningocócica
WO2010109324A1 (en) 2009-03-24 2010-09-30 Novartis Ag Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
EP2424562B1 (en) 2009-04-30 2015-10-07 Coley Pharmaceutical Group, Inc. Pneumococcal vaccine and uses thereof
TW201136603A (en) * 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
CN101785857B (zh) * 2010-03-05 2012-09-26 成都安特金生物技术有限公司 一种新的肺炎球菌结合疫苗及其制备方法
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
WO2011148382A1 (en) 2010-05-28 2011-12-01 Biological E Limited An improved process for the purification of capsular polysaccharides of haemophilus influenza - b, neisseria meningitis such as serotypes a, c, y and w-135, and other similar related capsular polysaccharides produced from both gram negative and gram positive microorganisms using aluminium phosphate with alcohol.
SI3170508T1 (sl) 2010-06-04 2020-01-31 Wyeth Llc Formulacije cepiva
CA2803239A1 (en) 2010-06-25 2011-12-29 Novartis Ag Combinations of meningococcal factor h binding proteins
WO2012117377A1 (en) 2011-03-02 2012-09-07 Novartis Ag Combination vaccines with lower doses of antigen and/or adjuvant
KR101315599B1 (ko) * 2011-10-25 2013-10-10 건국대학교 산학협력단 폐렴균점막다당질 유형14 （ｃｐｓ１４）와 호스래디시 퍼옥시다제의 당단백중합체
WO2013098589A1 (en) 2011-12-29 2013-07-04 Novartis Ag Adjuvanted combinations of meningococcal factor h binding proteins
US20150132339A1 (en) 2012-03-07 2015-05-14 Novartis Ag Adjuvanted formulations of streptococcus pneumoniae antigens
WO2013132043A1 (en) 2012-03-08 2013-09-12 Novartis Ag Combination vaccines with tlr4 agonists
KR102057217B1 (ko) 2012-06-20 2020-01-22 에스케이바이오사이언스 주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
CN104487086B (zh) * 2012-07-07 2019-08-30 巴拉特生物技术国际有限公司 无动物源的不含酒精的疫苗组合物及其制备方法
RU2645071C2 (ru) 2012-08-16 2018-02-15 Пфайзер Инк. Способы гликоконъюгирования и композиции
CN104602705A (zh) 2012-09-06 2015-05-06 诺华股份有限公司 血清组b脑膜炎球菌和d/t/p的联合疫苗
ES2651415T3 (es) * 2012-09-07 2018-01-26 Sk Chemicals Co., Ltd. Método de producción de un polisacárido capsular que tiene un serotipo neumocócico
KR20140075201A (ko) * 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
KR20140075196A (ko) * 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
CA2894260A1 (en) 2012-12-18 2014-06-26 Glaxosmithkline Biologicals S.A. Conjugates for protecting against diphtheria and/or tetanus
ITMI20130142A1 (it) * 2013-01-31 2014-08-01 Biosynth Srl Vaccini glicoconiugati comprendenti unita' di base di un costrutto molecolare esprimente epitopi multipli incorporati
CN104151426A (zh) * 2013-05-14 2014-11-19 北京天成新脉生物技术有限公司 肺炎链球菌十三种荚膜多糖单克隆抗体及其应用
CN103495161B (zh) * 2013-10-08 2019-06-18 江苏康泰生物医学技术有限公司 一种多元肺炎球菌荚膜多糖-蛋白质结合物的混合物及其制备方法
NZ755769A (en) 2014-01-21 2023-06-30 Pfizer Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP3583947B1 (en) 2014-01-21 2023-10-11 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
CA2937184A1 (en) 2014-01-21 2015-07-30 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
US11160855B2 (en) * 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
JP2017505792A (ja) 2014-02-14 2017-02-23 ファイザー・インク 免疫原性糖タンパク質コンジュゲート
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
HRP20230416T1 (hr) * 2015-01-15 2023-07-07 Pfizer Inc. Imunogeni pripravci, namijenjeni upotrebi u cjepivima protiv pneumokoka
TWI718144B (zh) * 2015-05-04 2021-02-11 美商輝瑞股份有限公司 Ｂ型鏈球菌多醣－蛋白質軛合物、製造軛合物之方法、含軛合物之免疫原性組成物、及其用途
EP3313436B1 (en) 2015-06-23 2020-12-23 Biological E Limited Multivalent pneumococcal conjugate vaccine
EP3325008A1 (en) 2015-07-21 2018-05-30 Pfizer Inc Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
EP3347042A4 (en) * 2015-09-10 2019-02-20 Inventprise, LLC. MULTIVALENT CONJUGATES WITH VIRUSUAL PARTICLES
WO2017085586A1 (en) 2015-11-20 2017-05-26 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
MX2019001341A (es) 2016-08-05 2019-07-04 Sanofi Pasteur Inc Composicion de conjugado de polisacarido neumococico multivalente-proteina.
CN109862908B (zh) * 2016-08-05 2023-05-02 圣诺菲·帕斯图尔公司 多价肺炎球菌多糖-蛋白质缀合物组合物
BR112019004303A2 (pt) * 2016-09-06 2019-05-28 Lg Chemical Ltd composição de conjugados multivalentes de polissacarídeo capsular pneumocócico-proteína portadora e uso da mesma
KR102608081B1 (ko) * 2016-09-30 2023-11-29 바이오로지칼 이 리미티드 폴리사카라이드-단백질 접합체를 포함하는 다가 폐렴구균 백신 조성물
US10751402B2 (en) 2016-11-09 2020-08-25 Pfizer Inc. Immunogenic compositions and uses thereof
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
MX2019007910A (es) * 2016-12-30 2019-12-05 Sutrovax Inc Conjugados de polipeptido-antigeno con aminoacidos no naturales.
CA3050622A1 (en) * 2017-01-20 2018-07-26 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
WO2018144438A1 (en) * 2017-01-31 2018-08-09 Merck Sharp & Dohme Corp. Methods for production of capsular polysaccharide protein conjugates from streptococcus pneumoniae serotype 19f
CN110225764A (zh) 2017-01-31 2019-09-10 默沙东公司 制备多糖-蛋白缀合物的方法
US11246918B2 (en) 2017-02-03 2022-02-15 Eva Barbara Schadeck Haemophilus influenzae saccharide-carrier conjugate compositions and uses thereof
JP7254707B2 (ja) * 2017-02-24 2023-04-10 メルク・シャープ・アンド・ドーム・エルエルシー 肺炎球菌コンジュゲートワクチン製剤
AU2018225099A1 (en) 2017-02-24 2019-07-25 Merck Sharp & Dohme Llc Enhancing immunogenicity of Streptococcus pneumoniae polysaccharide-protein conjugates
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
KR102028693B1 (ko) * 2017-04-27 2019-10-04 주식회사 유바이오로직스 스트렙토코커스 뉴모니아 협막 다당체의 생산방법
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
BR112019026192B1 (pt) 2017-06-10 2022-05-10 Inventprise, Llc Vacinas de conjugado multivalente com polissacarídeos de conjugado bivalente ou multivalente que fornecem imunogenicidade e avidez melhoradas
EP3641828B1 (en) 2017-06-23 2023-11-22 Affinivax, Inc. Immunogenic compositions
EP3431168A1 (en) * 2017-07-19 2019-01-23 Bayer Aktiengesellschaft Élimination de médicament non lié après couplage conjugué anticorps-médicament
US11395849B2 (en) 2017-09-07 2022-07-26 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
KR20200051004A (ko) 2017-09-07 2020-05-12 머크 샤프 앤드 돔 코포레이션 폐렴구균 폴리사카라이드 및 면역원성 폴리사카라이드-담체 단백질 접합체에서의 그의 용도
BR112020004502A8 (pt) 2017-09-07 2022-11-01 Merck Sharp & Dohme Polissacarídeos pneumocócicos e uso dos mesmos em conjugados imunogênicos polissacarídeo-proteína carreadora
US11491216B2 (en) * 2017-09-07 2022-11-08 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
SG11202005255PA (en) 2017-12-06 2020-07-29 Merck Sharp & Dohme Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
US11123417B2 (en) 2018-02-05 2021-09-21 Sanofi Pasteur Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
CN111757754A (zh) * 2018-02-05 2020-10-09 赛诺菲巴斯德有限公司 多价肺炎球菌多糖-蛋白质缀合物组合物
CA3096358A1 (en) 2018-04-18 2019-10-24 Sk Bioscience Co., Ltd. Streptococcus pneumoniae capsular polysaccharide and immunogenic conjugate thereof
JP7397000B2 (ja) 2018-04-30 2023-12-12 メルク・シャープ・アンド・ドーム・エルエルシー 凍結乾燥変異ジフテリア毒素のジメチルスルホキシド中均一溶液を提供する方法
KR20210005161A (ko) * 2018-04-30 2021-01-13 머크 샤프 앤드 돔 코포레이션 리오스피어로부터 스트렙토코쿠스 뉴모니아에 피막 폴리사카라이드 담체 단백질 접합체를 제조하는 방법
WO2019220304A1 (en) * 2018-05-14 2019-11-21 Tergene Biotech Pvt. Ltd. 15 valent pneumococcal polysaccharide conjugate vaccine
WO2020010016A1 (en) 2018-07-04 2020-01-09 Sutrovax, Inc. Self-adjuvanted immunogenic conjugates
WO2020010000A1 (en) 2018-07-04 2020-01-09 Sutrovax, Inc. Improved methods for the preparation of immunogenic conjugates
WO2020009993A1 (en) 2018-07-04 2020-01-09 Sutrovax, Inc. Improvements in immunogenic conjugates
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
BR112021004193A2 (pt) * 2018-09-12 2021-05-25 Affinivax, Inc. vacinas pneumocócicas multivalentes
WO2020075201A1 (en) * 2018-10-12 2020-04-16 Biological E Limited Multivalent pneumococcal polysaccharide-protein conjugate vaccine
EP3893926A1 (en) 2018-12-12 2021-10-20 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
JP7275277B2 (ja) 2018-12-19 2023-05-17 メルク・シャープ・アンド・ドーム・エルエルシー ストレプトコッカス・ニューモニエ多糖－タンパク質コンジュゲートを含む組成物およびその使用方法
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
US20220184199A1 (en) 2019-04-10 2022-06-16 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
CN110302375A (zh) * 2019-06-27 2019-10-08 康希诺生物股份公司 一种糖缀合物及其用途
US20220265803A1 (en) 2019-07-31 2022-08-25 Sanofi Pasteur Inc. Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same
CN112741901A (zh) * 2019-10-31 2021-05-04 北京科兴中维生物技术有限公司 一种含有5型肺炎链球菌荚膜多糖的疫苗及其制备方法
JP2021087420A (ja) 2019-11-01 2021-06-10 ファイザー・インク Ｅｓｃｈｅｒｉｃｈｉａ ｃｏｌｉ組成物およびその方法
KR20220146451A (ko) * 2020-01-17 2022-11-01 인벤트프라이즈 엘엘씨 다가 스트렙토코커스 백신
IL295713A (en) * 2020-02-21 2022-10-01 Pfizer Isolation of saccharides
WO2021165928A2 (en) 2020-02-23 2021-08-26 Pfizer Inc. Escherichia coli compositions and methods thereof
US20230321212A1 (en) 2020-08-26 2023-10-12 Pfizer Inc. Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
GB202016165D0 (en) 2020-10-12 2020-11-25 Optivalent Ltd Vaccine
WO2022084852A1 (en) 2020-10-22 2022-04-28 Pfizer Inc. Methods for purifying bacterial polysaccharides
IL302362A (en) 2020-10-27 2023-06-01 Pfizer ESCHERICHIA COLI preparations and their methods
CA3200602A1 (en) 2020-11-04 2022-05-12 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
JP2023549736A (ja) 2020-11-10 2023-11-29 ファイザー・インク コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用
US20220202923A1 (en) 2020-12-23 2022-06-30 Pfizer Inc. E. coli fimh mutants and uses thereof
KR102610292B1 (ko) * 2021-02-10 2023-12-04 에스케이바이오사이언스(주) 스트랩토코커스 뉴모니애 다당류와 운반체 단백질의 접합체 제조 방법
WO2022234416A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
EP4333879A1 (en) 2021-05-03 2024-03-13 Pfizer Inc. Vaccination against bacterial and betacoronavirus infections
AU2022281543A1 (en) 2021-05-28 2023-11-23 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
TW202306969A (zh) 2021-05-28 2023-02-16 美商輝瑞大藥廠 包含結合之莢膜醣抗原的免疫原組合物及其用途
CN114106210A (zh) * 2021-11-09 2022-03-01 北京智飞绿竹生物制药有限公司 一种23价肺炎球菌多糖疫苗的生产工艺
WO2023135515A1 (en) 2022-01-13 2023-07-20 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
GB2614916A (en) 2022-01-25 2023-07-26 Optivalent Ltd Intradermal vaccine complement
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
WO2023218322A1 (en) 2022-05-11 2023-11-16 Pfizer Inc. Process for producing of vaccine formulations with preservatives
WO2024062494A1 (en) 2022-09-19 2024-03-28 Biological E Limited Method for the purification of capsular polysaccharides

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US37741A (en) 1863-02-24 Improvement in bee-hives
US4097666A (en) * 1976-04-29 1978-06-27 The Institute Of Paper Chemistry Solvent system for polysaccharides
CA1115210A (en) 1977-11-28 1981-12-29 Dennis J. Carlo Pneumococcal vaccine
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
BE889979A (fr) 1981-08-14 1982-02-15 Smith Kline Rit Procede de preparation de polysaccharides bacteriens capsulaires antigeniques purifies, produits obtenus et leur utilisation
US4673574A (en) * 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US5360897A (en) * 1981-08-31 1994-11-01 The University Of Rochester Immunogenic conjugates of streptococcus pneumonial capsular polymer and toxin or in toxiad
US4902506A (en) 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US5097020A (en) * 1983-07-05 1992-03-17 The University Of Rochester Immunogenic conjugates
US4619828A (en) 1982-07-06 1986-10-28 Connaught Laboratories, Inc. Polysaccharide exotoxoid conjugate vaccines
CH660375A5 (it) 1983-02-08 1987-04-15 Sclavo Spa Procedimento per la produzione di proteine correlate alla tossina difterica.
US4761283A (en) * 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US4762713A (en) * 1983-07-05 1988-08-09 The University Of Rochester Boosting of immunogenic conjugate vaccinations by unconjugated bacterial capsular polymers
US4808700A (en) * 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
IT1187753B (it) 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
US5110908A (en) 1986-12-31 1992-05-05 Praxis Biologics, Inc. Haemophilus influenzae peptides and proteins
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
KR100188323B1 (ko) 1989-03-09 1999-06-01 이곤 이이 버어그 비타입성 헤모필루스 인플렌자에 대한 백신
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
CA2059693C (en) * 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
US5552146A (en) 1991-08-15 1996-09-03 Board Of Regents, The University Of Texas System Methods and compositions relating to useful antigens of Moraxella catarrhalis
US5769047A (en) 1991-12-23 1998-06-23 Zoche; Michael Engine with oil separator
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
ATE280235T1 (de) 1993-03-05 2004-11-15 Wyeth Corp Plasmid zur herstellung von crm-protein und diphtherie-toxin
JP3828145B2 (ja) 1993-09-22 2006-10-04 ヘンリー エム．ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディスン 免疫原性構成物の製造のための新規シアン化試薬を使った可溶性炭水化物の活性化方法
US5712118A (en) 1993-09-29 1998-01-27 Research Foundation Of State University Of New York Vaccine for branhamella catarrhalis
US5770213A (en) 1994-05-05 1998-06-23 American Cyanamid Company Purified nontypable haemophilus influenzae P5 protein as a vaccine for nontypable haemophilus influenzae infection
US5607846A (en) 1994-05-17 1997-03-04 Research Foundation Of State University Of New York Vaccine for moraxella catarrhalis
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5643725A (en) 1994-07-19 1997-07-01 American Cyanamid Company Sequence and analysis of LKP pilin structural genes and the LKP pili operon of nontypable haemophilus influenzae
US5565204A (en) 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
US6245337B1 (en) 1994-08-25 2001-06-12 Washington University Haemophilus adherence and penetration proteins
US6676948B2 (en) 1994-08-25 2004-01-13 Washington University Haemophilus adherence and penetration proteins
US5714354A (en) 1995-06-06 1998-02-03 American Home Products Corporation Alcohol-free pneumococcal polysaccharide purification process
US5695768A (en) * 1995-06-07 1997-12-09 Alberta Research Council Immunostimulating activity of Streptococcus pneumoniae serotype 8 oligosaccharides
US7341727B1 (en) 1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
CA2232975A1 (en) 1996-07-26 1998-02-05 American Cyanamid Company The nuca protein of haemophilus influenzae and the gene encoding that protein
WO1998028333A2 (en) 1996-12-20 1998-07-02 The Board Of Regents, The University Of Texas System USPA1 AND USPA2 ANTIGENS OF $i(MORAXELLA CATARRHALIS)
US6461618B1 (en) 1997-01-31 2002-10-08 American Cyanamid Company 74 kilodalton outer membrane protein from moraxella catarrhalis
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
FR2763244B1 (fr) 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
AU754256C (en) * 1997-12-23 2004-05-20 Pfizer Ireland Pharmaceuticals Procedures for the extraction and isolation of bacterial capsular polysaccharides for use as vaccines or linked to proteins as conjugate vaccines
CN1200730C (zh) * 1998-02-12 2005-05-11 惠氏控股有限公司 用白细胞介素－12配制的肺炎球菌和脑膜炎球菌疫苗
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
CA2233725A1 (en) * 1998-03-31 1999-09-30 Hemosol Inc. Hemoglobin-hydroxyethyl starch complexes
US7227011B2 (en) 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
KR20010089280A (ko) 1998-09-24 2001-09-29 리전츠 오브 더 유니버스티 오브 미네소타 스트렙토코쿠스 뉴모니애로부터의 인간 보체 ｃ3 분해폴리펩티드
PT1117435E (pt) 1998-09-30 2008-02-21 Us Gov Univ Health Sciences Holotoxina da cólera mutante como adjuvante
EP1034792A1 (en) 1999-03-11 2000-09-13 Pasteur Merieux Serums Et Vaccins Intranasal delivery of pneumococcal polysaccharide vaccines
EP1035137A1 (en) 1999-03-12 2000-09-13 Pasteur Merieux Serums Et Vaccins Method for the reductive amination of polysaccharides
GB9909077D0 (en) 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
SI1162999T1 (sl) 1999-03-19 2007-04-30 Glaxosmithkline Biolog Sa Vakcina proti Streptococcus pneumoniae
IL146895A0 (en) 1999-06-25 2002-08-14 American Cyanamid Co Production of the lipidated form of the peptidoglycan-associated lipoproteins of gram-negative bacteria
GB0011108D0 (en) 2000-05-08 2000-06-28 Microscience Ltd Virulence gene and protein and their use
GB0012079D0 (en) 2000-05-18 2000-07-12 Microscience Ltd Virulence gene and protein, and their use
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
NZ523319A (en) * 2000-06-29 2006-01-27 Glaxosmithkline Biolog Sa Vaccine compositions comprising Pw, TT, DT and H. influenzae type B (Hib) with a lower dose of Hib (5 mcg) compared with the standard does (10 mcg)
GB0020952D0 (en) 2000-08-24 2000-10-11 Microscience Ltd Genes and proteins and their uses
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
WO2002048029A1 (en) * 2000-12-13 2002-06-20 Sca Hygiene Products Zeist B.V. Recovery process for spent periodate
DK1355918T5 (da) 2000-12-28 2012-02-20 Wyeth Llc Rekombinant beskyttelsesprotein af streptococcus pneumoniae
KR100886095B1 (ko) 2001-04-16 2009-02-27 와이어쓰 홀딩스 코포레이션 폴리펩티드 항원을 암호화하는 신규한 스트렙토코쿠스 뉴모니애 개방형 판독 프레임 및 이를 포함하는 조성물
CA2449663A1 (en) 2001-06-07 2002-12-12 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
AU2002322380B2 (en) 2001-06-07 2006-11-02 Government Of The United States Of America As Represented By The Uniformed Services University Of The Health Sciences Mutant forms of cholera holotoxin as an adjuvant
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
WO2003009869A1 (en) 2001-07-26 2003-02-06 Chiron Srl. Vaccines comprising aluminium adjuvants and histidine
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
CA2473883A1 (en) 2001-11-29 2003-06-12 Wyeth Holdings Corporation Alloiococcus otitidis open reading frames (orfs) encoding polypeptide antigens, immunogenic compositions and uses thereof
GB0130215D0 (en) * 2001-12-18 2002-02-06 Glaxosmithkline Biolog Sa Vaccine
EP1490395A4 (en) 2002-03-15 2006-06-21 Wyeth Corp MUTANTS OF NON-TYPABLE HAEMOPHILUS INFLUENZAE P4 PROTEIN WITH REDUCED ENZYMATIC ACTIVITY
WO2003094961A1 (en) * 2002-05-09 2003-11-20 Massimo Porro Improved polysaccharide and glycoconjugate vaccines_____________
US20040096461A1 (en) * 2002-07-30 2004-05-20 Baxter Healthcare Corporation Chimeric multivalent polysaccharide conjugate vaccines
EP1549135A4 (en) * 2002-09-20 2006-01-11 Us Agriculture VACCINE AND ADJUVANT COMPOSITIONS
FR2850106B1 (fr) * 2003-01-17 2005-02-25 Aventis Pasteur Conjugues obtenus par amination reductrice du polysaccharide capsulaire du pneumocoque de serotype 5
CA2519511A1 (en) 2003-03-17 2004-09-30 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
WO2004094596A2 (en) 2003-04-16 2004-11-04 Wyeth Holdings Corporation Novel immunogenic compositions for the prevention and treatment of meningococcal disease
CN1241937C (zh) * 2003-07-04 2006-02-15 上海健益科技发展有限公司 多价肺炎球菌多糖结合疫苗
US9173931B2 (en) * 2003-08-06 2015-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Process for preparing polysaccharide-protein conjugate vaccines
PT1664319E (pt) * 2003-09-11 2010-06-17 Staat Der Nederlanden Vert Doo Processo para a produção de um polissacarídeo capsular para ser usado em vacinas de conjugados
FR2857364B1 (fr) 2003-12-08 2005-09-23 Aventis Pasteur Dosage des acides techoiques des bacteries gram+
SG149013A1 (en) 2003-12-17 2009-01-29 Wyeth Corp Immunogenic peptide carrier conjugates and methods of producing same
US20060022838A1 (en) 2004-07-27 2006-02-02 Fisher Richard A Speed limit indicia for traffic signals
EP2425851A1 (en) * 2005-04-08 2012-03-07 Wyeth LLC Multivalent Pneumococcal Polysaccharide-Protein Conjugate Composition
US7709001B2 (en) * 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070184072A1 (en) * 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US7955605B2 (en) * 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
ES2707499T3 (es) 2005-12-22 2019-04-03 Glaxosmithkline Biologicals Sa Vacuna de conjugado de polisacárido neumocócico
WO2008044611A1 (en) 2006-09-29 2008-04-17 Japan Poliomyelitis Research Institute Ipv-dpt vaccine
RS54349B1 (en) 2007-06-26 2016-02-29 Glaxosmithkline Biologicals S.A. VACCINE CONTAINING STREPTOCOCCUS PNEUMONIAE Capsular POLYSACCHARIDE CONJUGATES
CN101952321B (zh) 2007-12-24 2016-05-11 葛兰素史密斯克莱生物公司 重组rsv抗原
TW201136603A (en) 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
KR102057217B1 (ko) 2012-06-20 2020-01-22 에스케이바이오사이언스 주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
KR20140075196A (ko) 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
KR20140075201A (ko) 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
NZ755769A (en) 2014-01-21 2023-06-30 Pfizer Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
AU2018225099A1 (en) * 2017-02-24 2019-07-25 Merck Sharp & Dohme Llc Enhancing immunogenicity of Streptococcus pneumoniae polysaccharide-protein conjugates

Also Published As

Publication number Publication date
CA2986862C (en) 2022-09-27
DK1868645T3 (da) 2012-04-10
AR053354A1 (es) 2007-05-02
TW201438734A (zh) 2014-10-16
US20090130137A1 (en) 2009-05-21
JP2013006881A (ja) 2013-01-10
TWI445545B (zh) 2014-07-21
JP2008535838A (ja) 2008-09-04
EP2425851A1 (en) 2012-03-07
US10780160B2 (en) 2020-09-22
CN113198013A (zh) 2021-08-03
NZ562406A (en) 2009-09-25
US10716848B2 (en) 2020-07-21
ES2382048T3 (es) 2012-06-04
SI1868645T1 (sl) 2012-04-30
CN104815327A (zh) 2015-08-05
TWI511739B (zh) 2015-12-11
CY1112777T1 (el) 2016-02-10
KR20130048262A (ko) 2013-05-09
KR20150061019A (ko) 2015-06-03
BRPI0607025A2 (pt) 2009-07-28
EP1868645A1 (en) 2007-12-26
US20210283247A1 (en) 2021-09-16
CN101180079A (zh) 2008-05-14
WO2006110381A1 (en) 2006-10-19
US20180250390A1 (en) 2018-09-06
KR20070118700A (ko) 2007-12-17
US20060228380A1 (en) 2006-10-12
KR101730748B1 (ko) 2017-04-26
KR101588939B1 (ko) 2016-01-26
KR20150061021A (ko) 2015-06-03
KR20190104241A (ko) 2019-09-06
KR102220506B1 (ko) 2021-03-02
TWI386222B (zh) 2013-02-21
KR20150061018A (ko) 2015-06-03
KR101730749B1 (ko) 2017-04-26
MX358148B (es) 2018-08-07
RS52249B (en) 2012-10-31
EP2425855A1 (en) 2012-03-07
KR20150061020A (ko) 2015-06-03
US20190388537A1 (en) 2019-12-26
CN102716480B (zh) 2023-03-21
KR102564388B1 (ko) 2023-08-08
AU2006235013A1 (en) 2006-10-19
IL267125B (en) 2021-05-31
EP2425854A1 (en) 2012-03-07
US8895024B2 (en) 2014-11-25
CN108404126B (zh) 2022-10-18
CN102716480A (zh) 2012-10-10
KR102017842B1 (ko) 2019-09-03
KR102611449B1 (ko) 2023-12-06
CN108404126A (zh) 2018-08-17
SA06270323B1 (ar) 2010-10-05
EP4005595A1 (en) 2022-06-01
CA2878579A1 (en) 2006-10-19
CA2604363A1 (en) 2006-10-19
KR101730750B1 (ko) 2017-04-26
US20140314805A1 (en) 2014-10-23
JP2009161567A (ja) 2009-07-23
CL2016000566A1 (es) 2016-10-28
HK1257962A1 (zh) 2019-11-01
AR107018A2 (es) 2018-03-14
US9399060B2 (en) 2016-07-26
US20160158345A1 (en) 2016-06-09
CA2986862A1 (en) 2006-10-19
ATE548051T1 (de) 2012-03-15
JP4472770B2 (ja) 2010-06-02
BRPI0607025B8 (pt) 2021-05-25
CA2604363C (en) 2015-06-16
IL282638A (en) 2021-06-30
HRP20120278T1 (hr) 2012-04-30
KR20220042483A (ko) 2022-04-05
KR101298053B1 (ko) 2013-08-20
EP3311836A1 (en) 2018-04-25
KR20170086139A (ko) 2017-07-25
IL308456A (en) 2024-01-01
PL1868645T3 (pl) 2012-07-31
KR102378962B1 (ko) 2022-03-28
CA3165042A1 (en) 2006-10-19
US11191830B2 (en) 2021-12-07
CL2017002206A1 (es) 2018-03-23
TW200719911A (en) 2007-06-01
AU2006235013B2 (en) 2011-11-03
EP2425852A1 (en) 2012-03-07
IL267125A (en) 2019-08-29
HK1120416A1 (en) 2009-04-03
KR20230118200A (ko) 2023-08-10
CN113198013B (zh) 2024-02-20
BRPI0607025B1 (pt) 2019-11-12
US20200179508A1 (en) 2020-06-11
TW201212937A (en) 2012-04-01
IL228035A0 (en) 2013-09-30
EP2425856A1 (en) 2012-03-07
US8808708B2 (en) 2014-08-19
US20120237542A1 (en) 2012-09-20
KR20210022768A (ko) 2021-03-03
MX2019008863A (es) 2019-09-13
EP2425853A1 (en) 2012-03-07
ME01334B (me) 2013-12-20
MX2007012336A (es) 2007-11-21
PT1868645E (pt) 2012-05-17
CN113198012A (zh) 2021-08-03
CN101180079B (zh) 2012-07-18
US9981035B2 (en) 2018-05-29
MY145150A (en) 2011-12-30
IL186367A (en) 2013-09-30
IL186367A0 (en) 2008-01-20
CA2878579C (en) 2018-01-23
EP1868645B1 (en) 2012-03-07
JP5173920B2 (ja) 2013-04-03
JP5730261B2 (ja) 2015-06-03
HK1213184A1 (zh) 2016-06-30

Similar Documents

Publication Publication Date Title
HK1257962A1 (zh) 多價肺炎球菌多糖-蛋白質綴合物組合物
ZA200904331B (en) Multivalent pneumococcal polysaccharide-protein conjugate composition
ZA200904619B (en) Multivalent pneumococcal polysaccharide-protein conjugate composition
HRP20190037T1 (hr) Cjepivo na bazi konjugata pneumokoknih polisaharida
PT1968630T (pt) Composições imunogénicas de pcv2 multivalentes
AP2436A (en) Immunogenic composition
IL198466A0 (en) Immunization protocol against the 4 dengue serotypes
GB0526038D0 (en) Immunogenic composition
EP1976974A4 (en) Pneumococcal SEROTYPES
EP1963522A4 (en) MULTIVALENT MENINGOCOCCAL DERIVATIVE POLYSACCHARIDE-PROTEIN CONJUGATES AND VACCINE
GB0513071D0 (en) Immunogenic composition
ZA200805347B (en) Pneumococcal polysaccharide conjugate vaccine
GB0526041D0 (en) Immunogenic composition
GB0524204D0 (en) Immunogenic composition
GB0526040D0 (en) Immunogenic composition
GB0515556D0 (en) Immunogenic composition
GB0503143D0 (en) Immunogenic composition